Related references
Note: Only part of the references are listed.Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data What have we learned?
Rong Deng et al.
MABS (2011)
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Y. Joy Yu et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
What Can Be Inferred from the Interruption of the Semagacestat Trial for Treatment of Alzheimer's Disease?
Jeffrey Cummings
BIOLOGICAL PSYCHIATRY (2010)
β-Secretase Inhibitor Potency Is Decreased by Aberrant β-Cleavage Location of the Swedish Mutant Amyloid Precursor Protein
Hidekuni Yamakawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
Cynthia A. Lemere et al.
NATURE REVIEWS NEUROLOGY (2010)
The β-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential
Robert Vassar et al.
JOURNAL OF NEUROSCIENCE (2009)
Amyloid Precursor Protein Trafficking, Processing, and Function
Gopal Thinakaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Second generation of hydroxyethylamine BACE-1 inhibitors: Optimizing potency and oral bioavailability
Nicolas Charrier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
β-secretase as a therapeutic target for Alzheimer's disease
Arun K. Ghosh et al.
NEUROTHERAPEUTICS (2008)
Efficient inhibition of the Alzheimer's disease β-secretase by membrane targeting
Lawrence Rajendran et al.
SCIENCE (2008)
Immunotherapy for Alzheimer's disease:: attacking amyloid-β from the inside
Michal Arbel et al.
TRENDS IN IMMUNOLOGY (2007)
Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library
We-Ching Liang et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice
D Dominguez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
An inhibitor binding pocket distinct from the catalytic active site on human β-APP cleaving enzyme
MG Kornacker et al.
BIOCHEMISTRY (2005)
Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (β-secretase)
RT Turner et al.
BIOCHEMISTRY (2005)
High-affinity human antibodies from phage-displayed synthetic fab libraries with a single framework scaffold
CV Lee et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain:: implications for Alzheimer's disease therapeutics
SL Roberds et al.
HUMAN MOLECULAR GENETICS (2001)
Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation
Y Luo et al.
NATURE NEUROSCIENCE (2001)
BACE1 is the major β-secretase for generation of Aβ peptides by neurons
HB Cai et al.
NATURE NEUROSCIENCE (2001)
Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor
L Hong et al.
SCIENCE (2000)
Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein
XL Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
